This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Pulmonary Hypertension
+11

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Sponsored by Reata, a wholly owned subsidiary of Biogen

About this trial

Last updated a year ago

Study ID

RTA 402-C-1302

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

Yes

Accepting

18-75 Years
18 to 75 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 7 years ago

What is this trial about?

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.

What are the participation requirements?

Yes

Inclusion Criteria

1. Adult male and female patients ≥ 18 to ≤ 75 years of age upon study consent;

2. BMI > 18.5 kg/m²

3. Symptomatic pulmonary hypertension WHO class II and III;

4. WHO Group I, III, or V PH according to the following criteria:

1. If diagnosed with WHO Group I PAH, then on of the following subtypes:
- Idiopathic or heritable PAH;
- PAH associated with connective tissue disease;
- PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair;
- PAH associated with anorexigen or drug-induced toxicity;
- PAH associated with human immunodeficiency virus (HIV); or
2. If WHO Group III PH then primary diagnosis must be one of the following subtypes:
- Connective tissue disease associated ILD (CTD-ILD);
- Idiopathic pulmonary fibrosis (IPF);
- Nonspecific interstitial pneumonia (NSIP); or
3. If WHO Group V PH then patient must be diagnosed with sarcoidosis;

5. Had a diagnostic right heart catheterization performed and documented within 36 months prior to Day 1 that confirmed a diagnosis of PH

6. If WHO Group I, has been receiving no more than three (3) FDA-approved disease-specific PAH therapies except for intravenous (iv) prostacyclin/prostacyclin analogues. PAH therapy must be at a stable dose for at least 90 days prior to Day 1;

7. Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) 4-variable formula;

No

Exclusion Criteria

1. Participation in other interventional clinical studies involving pharmaceutical products being tested or used in a way different from the approved form or when used for an unapproved indication within 30 days prior to Day 1;

2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 3 months (90 days) prior to Day 1 or planned initiation during Part 1 of the study;

3. Stopped receiving any PH chronic therapy within 60 days prior to Day 1;

4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1;

5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during Screening after a period of rest;

6. Has systolic BP < 90 mm Hg during Screening after a period of rest;

7. WHO Group III or V patients who at rest require supplemental oxygen at a rate of >4 L/min and have peripheral capillary oxygen saturation levels <92%;

8. Has a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease,including but not limited to any of the following:

1. Congenital or acquired valvular disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension;
2. Pericardial constriction;
3. Restrictive or congestive cardiomyopathy;
4. Left ventricular ejection fraction < 40% per echocardiogram (ECHO) within 60 days of Day 1;
5. Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or anginal chest pain);

9. Acutely decompensated heart failure within 30 days prior to Day 1, as per Investigator assessment;

10. History of atrial septostomy within 180 days prior to Day 1;

11. History of obstructive sleep apnea that is untreated;

12. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C);

13. Serum aminotransferase (ALT or AST) levels > the upper limit of normal (ULN) at Screening;

14. For patients with HIV-associated PAH, any of the following:

1. Concomitant active opportunistic infections within 180 days prior to Screening;
2. Detectable viral load within 90 days prior to Screening;
3. Cluster designation (CD+) T-cell count < 200 mm3 within 90 days prior to Screening;
4. Changes in antiretroviral regimen within 90 days prior to Screening;
5. Using inhaled pentamidine

View clinical trial results on registries

Clinicaltrials.gov

Locations

Location

Status

For more information, view the full study details:

NCT02036970